Australia markets close in 4 hours 20 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
61.60+0.51 (+0.83%)
At close: 04:00PM EDT
61.80 +0.20 (+0.32%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close61.09
Bid61.60 x 1200
Ask61.80 x 1800
Day's range60.82 - 61.71
52-week range57.17 - 74.12
Avg. volume7,168,125
Market cap77.265B
Beta (5Y monthly)0.35
PE ratio (TTM)18.84
EPS (TTM)3.27
Earnings date26 Oct 2022 - 31 Oct 2022
Forward dividend & yield2.92 (4.78%)
Ex-dividend date14 Sept 2022
1y target est69.96
  • Motley Fool

    2 Reasons This Beaten-Down Stock Could Be About to Rebound

    Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.

  • Simply Wall St.

    What Kind Of Investors Own Most Of Gilead Sciences, Inc. (NASDAQ:GILD)?

    Every investor in Gilead Sciences, Inc. ( NASDAQ:GILD ) should be aware of the most powerful shareholder groups...

  • Business Wire

    Gilead Sciences to Acquire MiroBio

    FOSTER CITY, Calif. & OXFORD, England, August 04, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.